Q&A
-
Verily alum looks to improve access to retinal scans
CEO Vicky Demas joined Identifeye Health, a startup building an AI-supported retinal imaging device, after stints with Google’s sibling Verily and Grail.
By Elise Reuter • Nov. 21, 2024 -
Q&A
Insulet’s Trang Ly on overcoming ‘clinical inertia’ in diabetes care
Automated insulin delivery for Type 2 patients can help change minds among physicians who have been reluctant to prescribe pump therapy, the chief medical officer said in an interview.
By Susan Kelly • Aug. 27, 2024 -
Q&A
Ascensia’s new head of CGM talks plans for a 365-day sensor
Brian Hansen recently joined Ascensia, which markets Senseonics’ implantable glucose sensors. The current version lasts 180 days, but Senseonics is seeking FDA approval for a one-year sensor.
By Elise Reuter • Aug. 6, 2024 -
Q&A
Tandem CMO shares Mobi feedback, expansion plans
MedTech Dive caught up with Chief Medical Officer Jordan Pinsker to talk about early feedback on Tandem’s smallest insulin pump and what’s next for the device.
By Elise Reuter • July 29, 2024 -
Q&A
‘Our next frontier is prediction’: Medtronic on AI and heart disease
Stacey Churchwell, who leads the company’s cardiovascular diagnostics and services business, says artificial intelligence is reducing false positives in its insertable cardiac monitors, saving clinicians valuable time.
By Susan Kelly • July 22, 2024 -
Q&A
J&J’s Nisha Johnson on Ethizia wound-sealing patch, biosurgery market
With the recent launch of the hemostatic healing patch in Europe, J&J expects to lead the biosurgery and wound closure market.
By Elise Reuter • May 28, 2024 -
Q&A
Abbott’s Jennifer Jones-McMeans on treating PAD below the knee
Jennifer Jones-McMeans, a leader in Abbott’s vascular unit, discussed the company’s newly approved stent for the tough-to-treat condition in an interview with MedTech Dive.
By Susan Kelly • May 9, 2024 -
Q&A
Abbott’s Nadim Geloo on Triclip’s US launch, Edwards competition
The senior medical director for structural heart discussed the Triclip rollout, Edwards’ rival tricuspid treatment and Abbott’s aortic valve clinical trial.
By Susan Kelly • April 12, 2024 -
Q&A
J&J’s Aldo Denti on digital technology in orthopedics
The chairman of J&J subsidiary DePuy Synthes talked about how surgical robots and other technologies have contributed to procedures moving to outpatient facilities.
By Elise Reuter • Updated April 1, 2024 -
Q&A
Stryker’s next head of joint replacement talks about new revision, robotics products
Katherine Truppi will become president of Stryker’s joint replacement business on March 31 after more than 20 years at the company.
By Elise Reuter • March 22, 2024 -
Q&A
Abbott leader on the ‘hype’ and ‘reality’ of pulsed field ablation
Christopher Piorkowski, chief medical officer for the electrophysiology business, talks about the high expectations for the new atrial fibrillation treatment.
By Susan Kelly • March 1, 2024 -
Q&A
New GT Medical CEO Per Langoe on driving adoption of brain tumor therapy
Langoe, the former head of Palette Life Sciences, spoke about his plans to expand use of GT Medical’s cancer-fighting implant.
By Susan Kelly • Feb. 23, 2024 -
Q&A
Canary CEO Bill Hunter talks smart knee implant progress, new heart device
The company collaborated with Zimmer Biomet on its Persona IQ device, which is slated for a full market release this year. Canary is also working on an implantable monitor for heart failure patients.
By Elise Reuter • Feb. 15, 2024 -
Grail CEO predicts ‘transformative’ 2024 amid Illumina split
The liquid biopsy maker, which Illumina plans to divest, said it has made progress on a PMA application with the FDA for its Galleri multi-cancer early detection test.
By Susan Kelly • Dec. 19, 2023 -
Q&A
Moon Surgical CEO Anne Osdoit on readying a soft tissue robot for launch
With support from J&J’s venture capital arm and chip maker Nvidia, Moon is targeting a soft tissue surgery market dominated by Intuitive Surgical.
By Susan Kelly • Dec. 1, 2023 -
Q&A
Embecta CEO Dev Kurdikar talks about growth expectations, GLP-1s
The CEO said the company’s growth expectations have not changed in the near term, even with the rise of weight loss drugs.
By Elise Reuter • Nov. 21, 2023 -
Q&A
Stryker’s Lisa Kloes talks cementless implants, robotics as future of knee business
The manager of Stryker’s knee business also discussed the growing role of ambulatory surgery centers in orthopedics.
By Elise Reuter • Updated Nov. 8, 2023 -
Q&A
Baxter’s Heather Knight talks combating sepsis — and how AI can help
The company’s group president for medical products and therapies says the right fluid management practices can help save lives and lower hospital costs.
By Susan Kelly • Oct. 27, 2023 -
Q&A
GE HealthCare imaging CEO Jan Makela talks Mayo Clinic partnership
GE and Mayo Clinic plan to collaborate on imaging, artificial intelligence and cancer treatment.
By Elise Reuter • Oct. 6, 2023 -
Q&A
Bigfoot CEO talks Abbott acquisition, future of diabetes tech
Jeffrey Brewer hopes to see more integrated solutions for people with diabetes, starting with the company’s partnership with Abbott.
By Elise Reuter • Sept. 15, 2023 -
Q&A
Intuitive’s Tony Jarc on how AI is improving robotic surgery
The company aims to help surgeons achieve better results for patients and hospitals.
By Susan Kelly • Sept. 8, 2023 -
Q&A
ZimVie’s Rebecca Whitney sizes up the competition in cervical disc implants
The company is bringing new products to market as it faces more challengers in cervical disc replacement and tethering for scoliosis.
By Elise Reuter • Sept. 1, 2023 -
Q&A
Q&A: ‘Chaotic’ digital health market needs independent evaluation, new institute says
Independent evaluation could help the healthcare industry figure out which digital health products are backed by evidence, argues Caroline Pearson, executive director of the nonprofit Peterson Center on Healthcare.
By Emily Olsen • Aug. 11, 2023 -
Q&A: How Monogram’s CEO plans to disrupt robotic joint replacement surgery
The robot developer’s CEO, Benjamin Sexson, tells MedTech Dive why he believes the orthopedics market needs a fresh approach to joint reconstruction.
By Susan Kelly • Aug. 4, 2023 -
Q&A
Q&A: Penumbra CEO Adam Elsesser says new devices will drive changes in clot treatment
Penumbra has launched two devices that use computers to control suction of blood clots. That’s helped the company convert some surgeons from traditional methods of clot removal, like open surgery or drugs.
By Elise Reuter • July 7, 2023